Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 181Breast Neoplasms 154Prostatic Neoplasms 144Lung Neoplasms 139Glioblastoma 119Head and Neck Neoplasms 115Squamous Cell Carcinoma of Head and Neck 110Rectal Neoplasms 107Lymphoma 101Esophageal Neoplasms 100Pancreatic Neoplasms 76Esophageal Squamous Cell Carcinoma 71Leukemia 70Neoplasms 67Brain Neoplasms 67Lymphoma, Follicular 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Lymphoma, Non-Hodgkin 62Lymphoma, Large B-Cell, Diffuse 58Hodgkin Disease 56Uterine Cervical Neoplasms 53Central Nervous System Neoplasms 53Leukemia, Lymphocytic, Chronic, B-Cell 52Gliosarcoma 51Sarcoma 50Colorectal Neoplasms 50Neoplasm Metastasis 45Lymphoma, Large-Cell, Immunoblastic 45Glioma 44Burkitt Lymphoma 43

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2 Positive Esophagogastric Cancer × Radiotherapy × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡